Kenvue Inc. (NYSE:KVUE) Stock Now Rated “Hold” by Wall Street Brokerages

Shares of Kenvue Inc. (NYSE:KVUE) have been assigned an average rating of “Hold” from the ten research firms that are presently covering the firm, MarketBeat reports. Ten research analysts have rated the stock with a hold rating. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $18.43.

Several research firms have recently weighed in on KVUE. UBS Group cut their target price on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a report on Tuesday, August 11th. Wall Street Zen cut shares of Kenvue from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Zacks Research downgraded shares of Kenvue from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 7th. Weiss Ratings reiterated a “hold (c)” rating on shares of Kenvue in a research report on Friday, September 11th. Finally, Barclays increased their price target on Kenvue from $18.00 to $19.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 21st.

Hedge Funds Weigh In On Kenvue

Several hedge funds and other institutional investors have recently modified their holdings of the business. Johnson Financial Group Inc. purchased a new position in Kenvue in the second quarter worth approximately $26,000. GK Wealth Management LLC acquired a new stake in Kenvue during the third quarter worth $27,000. MV Capital Management Inc. acquired a new stake in Kenvue during the fourth quarter worth $28,000. CoreCap Advisors LLC raised its position in Kenvue by 64.9% in the second quarter. CoreCap Advisors LLC now owns 1,502 shares of the company’s stock valued at $29,000 after purchasing an additional 591 shares during the period. Finally, Reflection Asset Management purchased a new stake in Kenvue in the fourth quarter valued at $32,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

Kenvue Stock Performance

Shares of KVUE opened at $17.66 on Tuesday. Kenvue has a 12 month low of $14.02 and a 12 month high of $20.13. The stock has a fifty day moving average price of $18.43 and a 200-day moving average price of $18.17. The company has a current ratio of 1.01, a quick ratio of 0.71 and a debt-to-equity ratio of 0.67. The firm has a market cap of $33.91 billion, a PE ratio of 20.29, a P/E/G ratio of 1.62 and a beta of 0.48.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.31 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.32 by ($0.01). Kenvue had a net margin of 10.76% and a return on equity of 21.22%. The company had revenue of $3.96 billion for the quarter, compared to analyst estimates of $3.97 billion. During the same quarter last year, the company earned $0.29 EPS. The business’s revenue was up 3.0% compared to the same quarter last year. Equities research analysts predict that Kenvue will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, October 2nd. Investors of record on Monday, September 21st were issued a $0.21 dividend. This represents a $0.84 annualized dividend and a yield of 4.8%. The ex-dividend date was Monday, September 21st. Kenvue’s payout ratio is presently 96.55%.

Kenvue Company Profile

Kenvue Inc (NYSE: KVUE) is a consumer health company that develops, markets and sells self-care, skin health and essential health products. Its portfolio includes over-the-counter medicines, allergy and cold remedies, pain-relief products, oral-care items, wound-care products, baby care products and beauty brands.

Kenvue’s principal brands include Tylenol, Motrin, Zyrtec, Benadryl, Neutrogena, Aveeno, Listerine, Johnson’s and BAND-AID. The company distributes its products through pharmacies, retailers, e-commerce channels, healthcare providers and other commercial outlets in markets around the world.

Kenvue was formed through the separation of Johnson & Johnson’s consumer health business and became an independent publicly traded company in 2023.